International Business Machines Corp (IBM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
International Business Machines Corp (IBM) is a provider of global hybrid cloud and AI, and consulting solutions and services. The company develops system hardware and software, and offers infrastructure, hosting, financing solution and consulting services. The company provides its software and services in various areas including analytics, artificial intelligence, automation, blockchain, cloud computing, IT infrastructure, IT management, cybersecurity, and software development. The company also offers cloud, networking, security, technology consulting, application services, business resilience services, and technology support services. It serves automotive, banking and financial markets, electronics, energy and utilities, healthcare, insurance, life sciences, manufacturing, metals and mining, retail and consumer products, travel, and telecom industries. The company’s business operations span across the world. IBM is headquartered in Armonk, New York, the US.
International Business Machines Corp Key Recent Developments
Jun 17, 2026: IBM Study Finds Limited Control and Rising Dependencies Expose Enterprises in the Age of AI
Jun 02, 2026: Europe's Tech Sovereignty: Control, Choice and Independence
May 19, 2026: AusNet Launches Unified Customer Connections Platform To Accelerate Services Amid Rising Grid Demand
May 19, 2026: What Makes an IoT Cloud Platform Scalable?
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Exelixis Inc - Key Facts
Exelixis Inc - Key Employees
Exelixis Inc - Key Employee Biographies
Exelixis Inc - Major Products and Services
Exelixis Inc - History
Exelixis Inc - Company Statement
Exelixis Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Exelixis Inc - Business Description
Other Break-up: License Revenues
Performance
Other Break-up: Net Product Revenues
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: U.S.
Performance
R&D Overview
Exelixis Inc - Corporate Strategy
Exelixis Inc - SWOT Analysis
SWOT Analysis - Overview
Exelixis Inc - Strengths
Exelixis Inc - Weaknesses
Exelixis Inc - Opportunities
Exelixis Inc - Threats
Exelixis Inc - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Exelixis Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
Jun 22, 2026: Exelixis Updates Phase 3 STELLAR-303 Trial of Zanzalintinib Plus Atezolizumab in Metastatic Colorectal Cancer
May 19, 2026: Exelixis and Merck Collaborate on Phase 3 STELLAR-316 Trial for Resected Colorectal Cancer
Apr 15, 2026: Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics
Feb 09, 2026: Peptistar Receives the 2025 Best CDMO Award from Exelixis
Oct 20, 2025: Exelixis Reports Phase 3 STELLAR-303 Trial Results for Zanzalintinib in Metastatic Colorectal Cancer
Oct 18, 2025: Exelixis Reports CABINET Phase 3 Trial Results for CABOMETYX in Advanced Lung and Thymic Neuroendocrine Tumors
Aug 29, 2025: Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Aug 27, 2025: Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Jul 28, 2025: Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Feb 11, 2025: Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Exelixis Inc, Key Facts
Exelixis Inc, Key Employees
Exelixis Inc, Key Employee Biographies
Exelixis Inc, Major Products and Services
Exelixis Inc, History
Exelixis Inc, Subsidiaries
Exelixis Inc, Key Competitors
Exelixis Inc, Ratios based on current share price
Exelixis Inc, Annual Ratios
Exelixis Inc, Interim Ratios
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Exelixis Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Exelixis Inc, Performance Chart (2021 - 2025)
Exelixis Inc, Ratio Charts
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net